SEATTLE--(BUSINESS WIRE)--Acucela Inc., a clinical-stage biotechnology company focused on developing new treatments for blinding eye diseases, announced today that the first patient data from the ACU-4429 program were presented during a poster session at The Association for Research in Vision and Ophthalmology (ARVO) 2012 Annual Meeting. The presentation was made by John W. Chandler, MD, Vice President Clinical Affairs, Acucela and David G. Birch, PhD, Chief Scientific and Executive Officer, Retina Foundation of the Southwest. Please click the below link to access the poster:Prolonged Rod Visual Cycle Suppression with ACU-4429 in Patients with Geographic Atrophy
